Glymphatic system {#s1}
=================

The mammalian brain has the highest energy demand of the whole body. With merely 2% of the body weight, human brain consumes ∼20% of an individual's oxygen and glucose supply to maintain physiological brain function. Given high metabolic activity, effective elimination of the metabolic wastes is essential for homoeostasis of the microenvironment of brain cells. In the peripheral tissue, the lymphatic system collects the interstitial fluids that contain the metabolites, and enables the clearance of excessive metabolic wastes. However, as the central nervous system (CNS) lacks of classic lymphatic vessels, the clearance of metabolic waste products from brain has long been presumed solely via the cerebrospinal fluid (CSF) drainage pathways from the subarachnoid space mainly through arachnoid villi into the venous sinuses, and via cranial nerve sheaths into the peripheral lymphatic system.[@R1] The anatomical structures and mechanisms that regulate the clearance of parenchyma interstitial fluid (ISF) and solutes remain less clear.[@R2] With advanced in vivo imaging techniques, emerging data have revealed the presence of a clearance system, referred to as the glymphatic system, which clears extracellular solutes from the brain.[@R4]

The glymphatic system is a brain-wide CSF/ISF drainage system that enables the clearance of interstitial metabolic waste from the brain parenchyma. In vivo imaging studies in rodents show that arterial pulsations drive CSF into the brain parenchyma from the subarachnoid space via the abluminal side of penetrating arteries/arterioles.[@R4] Once CSF arrives at the microvascular level, aquaporin-4 (AQP4) channels located on the ensheathed astrocytic end-feet facilitate the convective flow movement of CSF containing water, ions and small molecule solutes including metabolic wastes into the interstitial space. These wastes then exit from the parenchyma via the paravenous spaces.[@R9] Ultimately, the excessive fluids and metabolic wastes are collected, at least partly, into deep cervical lymphatics that are adjacent to the internal jugular veins.[@R4] Recent experiments show that at least a portion of drained interstitial fluids and solutes re-enter subarachnoid spaces, where the metabolic wastes including amyloid-β were collected by meningeal lymphatic vessels, or enter the classical subarachnoid CSF drainage pathways via arachnoid villi and/or para-nerve sheathes into peripheral lymphatics.[@R11] Given its role on brain waste clearance that resembles peripheral lymphatic system and the importance of astrocytic AQP4 facilitated parenchyma CSF/ISF transport, this brain-wide CSF/ISF drainage pathway was named glymphatic (glia-lymphatic) system[@R4] (please see [figure 1](#F1){ref-type="fig"} for a schematic illustration of the glymphatic system). The waste clearance functions of glymphatic system have been further characterised. AQP4 gene deletion leads to profound reductions of interstitial influx of paravascular solutes and the clearance of interstitial solutes such as amyloid-β, indicating the pivotal role of astrocytic AQP4 in glymphatic transport.[@R4] During sleep, the interstitial space volume in mouse expands 60% over that in the awake state, which lowers resistance to the influx of para-arterial CSF to interstitial space, and therefore, accelerate fluxes of CSF/ISF along the glymphatic pathway and robustly enhances interstitial neurotoxic metabolite clearance including amyloid-β.[@R5] Additionally, different body postures and physiological pulsations evoked by respiratory and cardiac rhythm also influence the glymphatic drainage function.[@R12] Collectively, accumulating experimental data support the important role of the glymphatic system hypothesis in regulating brain metabolites clearance.

![Overview of glymphatic system. CSF enter the brain parenchyma along the para-arterial space. The AQP4 channels located on the astrocytic end-feet facilitate the convective flow movement of CSF--ISF within the interstitial space. The excessive ISF and its containing solutes then exit from the parenchyma via the para-venous spaces. AQP4, aquaporin-4; CSF, cerebrospinal fluid; ISF, interstitial fluid.](svn-2018-000203f01){#F1}

Glymphatic system in ageing and DM associated cognitive decline {#s2}
===============================================================

DM is a common metabolic disease in the middle-aged and older population, which is associated with cognitive decline and an increased risk of developing dementia in the elderly.[@R14] While advanced age remains a prominent risk factor for cognitive decline and dementia, DM accelerates the cognitive impairment and increases the risk for dementia in the elderly.[@R14] Given the multifaceted nature of the metabolic disease, multiple pathological mechanisms have been implicated in the development of cognitive abnormalities, such as cerebral vascular complications, disturbances of glucose homoeostasis, oxidative stress and neurotoxicity, and defective in amyloid metabolism.[@R18] Emerging evidence also suggests that DM and ageing are associated with a dramatic decline in glymphatic function, which may negatively affect cognitive function.

In the normal aged brain, several structural and functional abnormalities in the glymphatic system including the reduction of cerebrovascular pulsatility and the depolarisation of astrocytic AQP4 hamper glymphatic system function.[@R8] As parenchymal accumulation of metabolic wastes including amyloid-β is an established pathological substrate in cognitive decline during ageing and Alzheimer's disease,[@R19] it was postulated that glymphatic dysfunction contributes to ageing associated cognitive decline via impairing the parenchyma amyloid-β clearance.[@R8] Indeed, in an animal model of Alzheimer's disease, the reduction of glymphatic transport preceded to the appearance of parenchymal amyloid-β deposits, suggesting that glymphatic dysfunction may be a causative factor for Alzheimer's disease pathology.[@R21]

The prevalence of cognitive dysfunction is high in patients with diabetes, especially among the elderly.[@R22] However, due to lack of animal models, there are few preclinical studies to investigate the effect of DM on glymphatic system function and its contributions to cognitive impairment during ageing. Using a chemically induced DM model in the middle-aged rats, a recent study showed that DM accelerates the progression of hippocampal related cognitive decline that mimics the clinical deterioration of cognitive dysfunction observed in aged patients with type 2DM.[@R23] Subsequent study showed that after intracistern magna injection of small molecule contrast agent gadolinium-diethylene-triaminepentaacetic acid (Gd-DTPA) and CSF/ISF fluorescence tracer, MRI and ex vivo fluorescence microscopic imaging studies reveal that glymphatic drainage of MRI and fluorescence tracers in the hippocampus and hypothalamus are profoundly reduced in the middle-aged DM rats, which are highly correlated with the learning and memory deficits.[@R23] In parallel, DM induced cognitive function impairment in the middle-aged rats was associated with hippocampal astrocyte activation, loss of paravascular AQP4 immunoreactivity and microvascular disruption, all of which are key anatomical and functional components which facilitate glymphatic system function.[@R24] Together, the observed correlation between the hippocampal glymphatic dysfunction and the cognitive deficits in the middle-aged DM rats emphasises the key role of glymphatic system in DM and ageing associated cognitive deficits. However, as ageing and DM associated cognitive dysfunctions are attributed to a dynamic accumulation of various neuropathogenic processes, the dysfunction of glymphatic system may represent a composite of neuropathological alterations that underlie ageing and DM associated cognitive deficits.

The physiological and pathophysiological significance of the glymphatic system in the brain is being actively investigated. There are controversies regarding the anatomical elements and flow dynamics arising from the discovery of glymphatic system.[@R25] Recent evidence on the existence of meningeal lymphatic vessels added another layer of regulatory mechanisms of glymphatic system on cognitive function.[@R3] Indeed, a recent study shows while learning and memory impairments observed in aged mouse is accompanied with decreased meningeal lymphatic vessels coverage and impairment of the glymphatic CSF/ISF transport, enhancing meningeal lymphatic drainage with vascular endothelial growth factor C treatment accelerates parenchymal glymphatic CSF/ISF transport and improves learning and memory performance in the aged mouse.[@R11] These data reflect our growing understanding of the complexity of the role glymphatic system and its interaction with other brain drainage mechanisms in regulating cognitive function.

In conclusion, emerging data demonstrate that the glymphatic system mediated CSF--ISF exchange is instrumental in maintaining homoeostasis of the neural microenvironment. Ageing and DM incited impairments of the glymphatic system may predispose to the development of cognitive dysfunction and neurodegenerative diseases. However, in recognition of the complexity of the potential pathological mechanisms implicated in ageing and DM associated cognitive decline, the relative contribution and causative interplay between glymphatic system and other neuropathological factors in DM and ageing induced cognitive deficits warrant further investigation. Defining DM and ageing associated glymphatic system disruption may potentially have important clinical implications in predicting, preventing and providing potential targets for new treatment paradigms for cognitive decline.
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